Skip to main content
OpenTrials
Completed

NCT Number: NCT04583202

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

The aim of this study is to assess the nasal and conjunctival response in subjects allergic to birch pollen during controlled exposures in the ALYATEC environmental exposure chamber (EEC)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alyatec

Strasbourg, Grand Est, 67000, France

About this study

This is a single-center, single-blind, placebo-controlled study. The first part of the study consists of 6 exposure sessions in Alyatec EEC, including placebo and birch pollen allergen exposures.

The second part of the study involves in-field evaluations of rhinitis and conjunctivitis symptoms during birch pollen season.

Alyatec environmental exposure chamber, also called allergen challenge chamber, allows to evaluate allergic symptoms in standardized and reproducible conditions. All the metrological parameters (temperature, air flow, hygrometry ...) are controlled as well as the allergen concentration diffused in the room.

This enables to induce and observe rhinitis, conjunctivitis and asthma symptoms for up to 20 patients at the same time, in a reproducible way and without the potential perturbations or contaminations of the natural environment.

The current study aims to get specific information about allergic symptoms induced in the Alyatec EEC chamber in patients sensitized to birch pollen allergen.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A clinical history of allergic rhinitis to birch pollen for at least 2 consecutive pollen seasons requiring the taking of a symptomatic drug with or without associated asthma
  • Positive skin prick tests for birch pollen (> 3 mm)
  • IgE specific to birch > 0.75 kUI / L.
  • Positive unit rapid nasal provocation test for birch pollen
  • Subjects having signed informed consent
  • Subjects affiliated to a social security scheme
  • Subjects able to understand and complete the procedures related to the study
  • Women of childbearing potential should have a negative pregnancy test throughout the study period with effective contraception

Exclusion criteria

  • Specific immunotherapy (SIT) for birch allergens for more than a month in the 3 years preceding the screening
  • Current use of Specific immunotherapy for another allergen
  • Medical history of anaphylaxis following exposure to birch pollen
  • Medical history of anaphylaxis linked to another allergen in the last 6 weeks
  • Nasal polyps, nasal septum deviation or diagnosis of non-allergic rhinitis
  • Subjects allergic to indoor environmental allergens (cat allergens, mold, dust mites) with - Obvious exposure to these allergens.
  • Uncontrolled allergic pathology (rhinitis, conjunctivitis)
  • Forced expiratory volume in 1 second (FEV1) <70% of predicted normal values
  • Moderate to severe asthma (GINA 3 to 5)

Treatment and study plan

Exposure to Placebo

Other

Patients are exposed to a placebo for 4h in the Alyatec EEC

Exposure to allergen

Other

Patients are exposed to birch pollen allergens for 4h in the Alyatec EEC

Primary outcomes

  1. Total Nasal Symptom Score

    Time frame: 4 hours exposure

    To assess the nasal response during exposure to birch allergens compared to placebo in the ALYATEC EEC.

Secondary outcomes

  1. Visual Analogue Scale for rhinitis

    Time frame: 4 hours exposure

    To evaluate the intensity of the nasal response during exposure to birch allergens compared to placebo in the ALYATEC EEC.

  2. Total Nasal Symptom Score

    Time frame: 4 hours exposure

    To evaluate the intensity of the nasal response during exposure to birch allergens compared to placebo in the ALYATEC EEC.

  3. Visual Analogue Scale for conjunctivitis

    Time frame: 4 hours exposure

    To evaluate the intensity of the conjunctival response during exposure to birch allergens compared to placebo in the ALYATEC EEC.

  4. Total Ocular Symptom Score

    Time frame: 4 hours exposure

    To evaluate the intensity of the conjunctival response during exposure to birch allergens compared to placebo in the ALYATEC EEC.

  5. Peak Nasal Inspiratory Flow

    Time frame: 4 hours exposure

    To evaluate the nasal obstruction during exposure to birch allergens compared to placebo in the ALYATEC EEC.

Sponsors and collaborators

Lead sponsor

Alyatec

Industry

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Oct 12, 2020
Registry last updated
Jun 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.